Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early low-dose calcineurin inhibitor plus sirolimus after kidney transplantation
ChiCTR2400086269Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sirolimus in kidney allograft rejection and Chronic Allograft Kidney Disease (CKaD) (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Glomerular filtration rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
kidney allograft rejectionChronic Allograft Kidney Disease (CKaD)
Beyond the preview
Go deeper on ChiCTR2400086269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086269.